Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

Melanoma Research

Volumn 21, Issue 1, 2011, Pages 84-90

  Bedikian, Agop Y ^a   Johnson, Marcella M ^a   Warneke, Carla L ^a   Papadopoulos, Nicholas E ^a   Kim, Kevin B ^a   Hwu, Wen Jen ^a   McIntyre, Susan ^a   Rohlfs, Michelle ^a   Homsi, Jade ^a   Hwu, Patrick ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biochemotherapy; Complete response; Long term survival melanoma; Systemic therapy

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; LACTATE DEHYDROGENASE; PACLITAXEL; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REMISSION; SEX DIFFERENCE; SKIN NEOPLASMS; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; LOGISTIC MODELS; MALE; MELANOMA; NEOPLASM METASTASIS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; SEX FACTORS; SKIN NEOPLASMS; TREATMENT OUTCOME; VINBLASTINE;

EID: 79952747501     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328341445f     Document Type: Article

References (38)

1. Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia, USA: Lippincott, Williams & Wilkins; 2001.
2. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and DTIC (CVD) for metastatic melanoma. Cancer 1989; 64:2024-2029. (Pubitemid 19280399)
3. Ahmann DL, Creagan ET, Hahn RG, Edmonson JH, Bisel HF, Schaid DJ. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989; 63: 224-227. (Pubitemid 19035009)
4. Buzaid AC, Legha SS, Winn R, Belt R, Pollock T, Wiseman C, et al. Cisplatin (C), vinblastine (V), DTIC (D) (CVD) versus DTIC alone in metastatic melanoma: preliminary results phase III cancer community oncology program (CCOP). Proc Am Soc Clin Oncol 1993; 12:389.
5. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multi-center randomized trial of the Dartmouth regimen versus DTIC in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-2751. (Pubitemid 29415231)
6. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
7. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16 2921-2929. (Pubitemid 28417410)
8. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol 2007; 25:5426-5434. (Pubitemid 350232219)
9. Johnston SRD, Constenla DO, Moore J, Atkinson H, A'Hern RP, Dadian G, et al. Randomized Phase II trial of BCDT [carmustine (BCNU), cisplatin, DTIC (DTIC), and Tamoxifen] with or without interferon alpha (IFN-α) and interleukin-2 (IL-2) in patients with metastatic melanoma. Br J Cancer 1998; 77:1280-1286. (Pubitemid 28140617)
10. Keilholz U, Punt CJ, Gore M, Kruit W, Lienard D, Thomas J, et al. DTIC, cisplatin and Interferon-Alfa-2b with or without Interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organization for Research and Treatment of Cancer Melanoma. J Clin Oncol 2005; 27:6747-6755.
11. Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicenter trial of the Dermatologic Oncology Group (DeCOG). Br J Cancer 2001; 84:1036-1042. (Pubitemid 32448498)
12. Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Brocker EB, Neumann C, et al. Combination chemotherapy with or without s.c. IL-2 and 1FN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002; 86:179-184. (Pubitemid 34185142)
13. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, DTIC, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17:968-975. (Pubitemid 29109330)
14. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results from a Phase III Randomized Trial. J Clin Oncol 2002; 20:2045-2052. (Pubitemid 34408794)
15. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM, et al. A prospective randomized Phase III trial of concurrent Biochemotherapy (BCT) with cisplatin, Vinblastine, DTIC (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-c#2847 coordinated intergroup trial. J Clin Oncol 2003; 22:708.
16. Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and DTIC (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 19996; 7:827-835.
17. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a Biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, DTIC, interferon alpha, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16:1752-1759. (Pubitemid 28234719)
18. Legha S, Ring S, Bedikian A, Eton O, Plager C, Papadopoulos N, et al. Lack of Benefit from Tamoxifen (T) Added to a Regimen of Cisplatin (C), Vinblastine (V), DTIC (D) and Alpha Interferon (IFN) in Patients (pts) with Metastatic Melanoma (MM). J Clin Oncol 1993; 12:388.
19. Papadopoulos N, Bedikian AY, Ring S, Kim KB, Camacho L, Eton O. Phase II study of CTD (cisplatin, paclitaxel, DTIC) in metastatic melanoma (MM). J Clin Oncol 2003; 22:718.
20. Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N. Development and results of Biochemotherapy in metastatic melanoma: the University of Texas MD Anderson Cancer Center Experience. Cancer J 1997; 3:S9-S15.
21. Kim B, Eton O, East MJ, Hodges C, Papadopoulos N, Grimm EA, et al. Pilot Study of high dose concurrent biochemotherapy for advanced melanoma. Cancer 2004; 101:596-603. (Pubitemid 38970611)
22. Papadopoulos NE, Eton O, Kim B, Camacho LH, Hwu P, Bedikian AY. Phase II study of 'hybrid' biochemotherapy for advanced melanoma. J Clin Oncol 2006; 24 (Suppl):18S.
23. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos N, Kim K, Hwu WJ, et al. Prognostic factors that determine the Long-term Survival of patients with unresectable metastatic melanoma. Cancer Invest 2008; 26:624-633. (Pubitemid 351918588)
24. Handbook for reporting results of cancer treatment. World Health Organization 1979.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53:457-481.
26. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society 1972; 34:187-202.
27. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1:710-719. (Pubitemid 14202071)
28. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu W-J, et al. Prognostic factors associated with complete response with systemic therapy in patients with stage IV melanoma. In: Jimbow K. XXth International Pigment Cell Conference-IPCC and V International Melanoma Research Congress-IMRC, International Proceedings. Bologna, Italy: MEDIMOND S.r.l.; 2008, pp. 161-170.
29. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K, et al. Melanoma disease site group of cancer care ontario's program in evidence-based care. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007; 33:484-496.
30. Allen IE, Kupelnick B, Kumashiro M, Luo D, Ross SD, Wolin MJ. Efficacy of interleukin-2 in the treatment of metastatic melanoma. Systematic review and meta-analysis. Cancer Ther 1998; 1:168-173.
31. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J 2000; 1 (Suppl 6):S11-S14.
32. Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, Rassner G, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. Cancer 1997; 79:2345-2353.
33. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16:1103-1111. (Pubitemid 28108747)
34. Keilholz U, Martus P, Punt CJ, Kruit W, Mooser G, Schadendrof D, et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomized EORTC Melanoma Group trial comparing interferon-alpha2a (IFN alpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 2002; 38:1501-1511. (Pubitemid 34756403)
35. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228:307-319. (Pubitemid 30191694)
36. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993; 71:2995-3005. (Pubitemid 23145529)
37. Barth A, Wanek LA, Morton DL. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181:193-201.
38. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000; 18:3782-3793.